ArticleNature communications2026
Standardized chronic disease management reduces comorbidity risk in China.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Standardized chronic disease management reduces comorbidity risk in China.Nature communications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Non-communicable chronic diseases pose a significant public health challenge worldwide. China has launched a nationwide standardized Chronic Disease Patient Management program to provide primary care for patients with hypertension and type 2 diabetes, but its effect on reducing risks of other chronic diseases remains unclear. Here we show, using linked health profiles and medical records from 26 million residents in Shenzhen, China, that program enrollment is associated with lower comorbidity risk among 701,759 patients with newly diagnosed hypertension and 320,179 patients with newly diagnosed type 2 diabetes between 2017 and 2023. Instrumental variable analyses indicate that enrollment reduces overall comorbidity risk by 9% and 14%, respectively. Participants show lower risks for more than 20 chronic diseases. Intervention-specific analyses reveal heterogeneous effects, with alcohol-use, medication-adherence, and psychological support interventions reducing risks of multiple chronic diseases in both patient groups, whereas smoking cessation intervention shows more complex risk patterns among patients with hypertension. These findings support standardized chronic disease management for reducing comorbidity risk and highlight the need for personalized follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.